Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system

BACKGROUND: On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization for Ad.26.COV2.S COVID-19 vaccine. As part of post-authorization safety surveillance, the FDA has identified a potential safety concern for thrombocytopenia following receipt of Ad.26.COV2....

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Emily Jane, Dimova, Rositsa B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149044/
https://www.ncbi.nlm.nih.gov/pubmed/35667915
http://dx.doi.org/10.1016/j.vaccine.2022.05.078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149044/
https://www.ncbi.nlm.nih.gov/pubmed/35667915
http://dx.doi.org/10.1016/j.vaccine.2022.05.078

Ejemplares similares